14.2亿元！华润医药又抛售一药企

Core Viewpoint - China Resources Pharmaceutical announced the potential sale of approximately 17.87% equity in Tianmai Biotechnology, with a listing price of around RMB 1.42 billion, marking its exit from being a core shareholder after a 10-year investment [1][4]. Group 1: Company Overview - Tianmai Biotechnology, established in 2010, focuses on the development of diabetes-related products and services [1]. - The company has a diverse shareholder structure with 21 shareholders, where China Resources Pharmaceutical Investment holds a 20% stake, making it the largest and core shareholder [1]. Group 2: Investment History - China Resources Pharmaceutical initially invested in Tianmai Biotechnology due to its focus on the significant diabetes market and the potential of oral insulin ORM-D-0801 [3]. - The investment history includes a previous sale of 14.12% equity for approximately HKD 1.147 billion in 2017, triggered by Tianmai's failure to obtain GMP certification [3][4]. Group 3: Product Development - Tianmai Biotechnology has partnered with Singapore's Vanier Company for joint research and development of biopharmaceuticals, establishing bases in Israel and China [2]. - The company developed ORM-D-0801, an oral insulin product aimed at treating type 2 diabetes, which faced challenges in clinical trials [6]. Group 4: Market Challenges - The oral insulin ORM-D-0801 failed to meet primary and secondary endpoints in a Phase III trial, leading to its rejection by the National Medical Products Administration in December 2025 [7]. - Following the failure of ORM-D-0801, Tianmai Biotechnology must return to the traditional insulin market, facing competition from established players without the scale or technology reserves [7]. Group 5: Strategic Decisions - The decision to sell Tianmai Biotechnology's stake reflects China Resources Pharmaceutical's broader strategy of divesting non-core assets amid changing market conditions [8]. - This strategic move indicates a proactive approach to risk management and resource allocation in a complex market environment [8].